PFIZER’S CENTERS FOR THERAPEUTIC INNOVATION
REQUESTS PROPOSALS FOR THERAPEUTIC TARGETS
Deadline: April 29th 2019

Pfizer’s Centers for Therapeutic Innovation (CTI) is a unique joint drug-discovery model that partners with leading academic medical centers to rapidly translate novel target opportunities into new medicines.

CTI collaborations offer:
- Funding for research costs and postdocs
- Hands-on collaboration with dedicated Pfizer drug-development team
- Financial incentives: milestone and royalty payments for successful programs
- Access to Pfizer’s science and technologies
- Flexible publishing rights
- Involvement of CTI’s foundation alliances

Modalities Considered
- Biologics: antibodies, proteins, fusion proteins, antibody conjugates, conditional activated biotherapeutics for enhance tissue/tumor targeting

Projects better suited to small molecule approaches may also be considered under an alternative Pfizer program

Areas of Interest for Spring 2019

Disease Areas:
- Cancer: select solid tumors: colorectal, breast, lung, prostate, pancreatic, hepatocellular, ovarian cancers
- Autoimmunity/Inflammation: inflammatory bowel disease, Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis, atopic dermatitis, psoriasis, Rheumatoid arthritis.
- Metabolic: cardiometabolism, cachexia
- Rare: monogenic hematologic (non-malignant) disorders, neurologic/neuromuscular disorders, inborn errors of metabolism, endocrine, renal and cardiovascular diseases. Ultra-rare indications are not in scope at this time

Target/Pathway Focus:
- DNA damage recognition and repair (e.g. replication stress or repair mechanisms)
- Tissue–resident immune modulation (e.g. adaptive or innate mechanisms, immunometabolism, etc.)
- Immune activators /enhancers (e.g. nucleic acid sensing, toll-like receptors etc)
- Modulation of senescence in cancer and non-neoplastic indications
- DNA repeat expansion diseases (e.g. Huntington’s disease, amyotrophic lateral sclerosis, myotonic dystrophy or frontotemporal dementia)
- Regulation of epithelial or mucosal barrier function including autophagy, host-microbe interactions
- Modulation of fibrosis pathways, either metabolism/stress-induced or inflammation-induced (possibly tumor-driven)
- Regulation of antigen-specific immune tolerance induction
- Emerging metabolic regulators in heart failure, satiety, nonalcoholic steatohepatitis and muscle biology

Pre-Proposal Format
Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

The pre-proposal template is available at: innovation.partners.org/about/special-programs

Information & Submission
We encourage researchers to discuss their ideas before submission: please contact Arpita Maiti at arpita.maiti@pfizer.com and Julian Peat at jpeat@partners.org.

Submit pre-proposals to PHSstrategicalliances@partners.org by April 29th 2019